TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer
- 1 April 2020
- journal article
- research article
- Published by Elsevier in Clinical Genitourinary Cancer
- Vol. 18 (2) , 148-154
Abstract
No abstract availableKeywords
Funding Information
- Tulane Cancer Center
This publication has 23 references indexed in Scilit:
- Molecularly targeted therapies for p53-mutant cancersCellular and Molecular Life Sciences, 2017
- Phenotypic diversity of circulating tumour cells in patients with metastatic castration‐resistant prostate cancerBJU International, 2016
- Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall SurvivalFrontiers in Pharmacology, 2016
- Combination of circulating tumor cell enumeration and tumor marker detection in predicting prognosis and treatment effect in metastatic castration-resistant prostate cancerOncotarget, 2015
- Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNAPLOS ONE, 2015
- Integrative Clinical Genomics of Advanced Prostate CancerCell, 2015
- Heterogeneity of Li-Fraumeni Syndrome links to unequal gain-of-function effects of p53 mutationsScientific Reports, 2014
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortalScience Signaling, 2013
- Mutant p53: one name, many proteinsGenes & Development, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012